Tolerability of Ropeginterferon Alfa-2b Add-on to Ongoing Ruxolitinib Therapy in Myelofibrosis

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
Tolerability of Ropeginterferon Alfa-2b Add-on to Ongoing Ruxolitinib Therapy in Myelofibrosis	Hemic and Lymphatic Diseases, Myeloproliferative Disorders, bone marrow disorder, hematologic disorder, primary myelofibrosis	Recruiting	Phase 1	2026-10-01		NCT07521046

2 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
PharmaEssentia	11
University of Utah	319

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
Huntsman Cancer Institute at University of Utah	Salt Lake City	United States	28

Clinical trials